Abstract. We herein describe the findings from the trifluridine/tipiracil (TAS-102) Compassionate Use program in Latvia, set up prior to marketing authorization for the management of pretreated patients with metastatic colorectal cancer (mCRC). The efficacy and safety of TAS-102 in patients with refractory mCRC were evaluated in the phase III trial RECOURSE. A previous report confirmed neutropenia and duration of previous treatment for mCRC as prognostic factors in TAS-102 users. The aim of the present study was to analyze possible prognostic factors, such as neutropenia, in TAS-102 responders. A retrospective analysis of 14 patients who received TAS-102 chemotherapy in two institutions in Latvia
Introduction
Metastatic colorectal cancer (mCRC) is one of the leading types of cancer in developed countries. Despite treatment and diagnostic advances, the mortality rates of mCRC remain high, with a patient survival of 24-30 months. In Latvia, ~1,000 patients with colon and rectum cancer are diagnosed annually, 25% of whom are metastatic at presentation (1).
Cytotoxic agents, including a fluoropyrimidine, irinotecan and oxaliplatin, and antibodies, such as bevacizumab (an antivascular endothelial growth factor monoclonal antibody) and cetuximab and panitumumab (anti-epidermal growth factor receptor monoclonal antibodies) may significantly improve the survival of patients with unresectable mCRC. However, chemotherapy-refractory mCRC patients represent a major challenge for medical oncologists in terms of selection of further treatment.
Trifluridine/tipiracil (FTD/TPI), also referred to as TAS-102, is a combination of an antineoplastic thymidinebased nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor tipiracil hydrochloride at a molar ratio of 1:0.5. The efficacy and safety of FTD/TPI in patients with mCRC who are refractory to standard therapies were evaluated in the RECOURSE trial (2). ) was administered orally twice daily, for 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period, thus completing one cycle. The regimen was repeated every 4 weeks. The dose was recommended as standard in all sites participating in the Lonsurf Compassionate Use program (2) . Treatment was discontinued upon clinically or radiologically confirmed disease progression.
Patients and methods

Study
Statistical analysis. Progression-free survival (PFS) was calculated from the start of FTD/TPI until clinical or radiological progression, and overall survival (OS) was calculated from the start of FTD/TPI until death from any cause or censoring at the last follow-up. The median OS and PFS (mOS and mPFS, respectively) were estimated using the Kaplan-Meier method. The log-rank test was used to calculate any significant differences between the subgroups (patients with vs. without grade 3-4 neutropenia, and duration of previous treatment ≤ vs. >18 months) by univariate analysis. Significance levels were set at P<0.05. All statistical analyses were performed by MedCalc software, version 16.4.8 (MedCalc Software, Ostend, Belgium).
Results
Patients. Of the 15 patients, 14 received FTD/TPI treatment in the Lonsurf Compassionate Use program in Latvia between
April 2016 and January 2017 in the two participating institutions (1 patient was excluded from the program due to rapid cancer progression). The clinical characteristics of the participants are listed in Table I . A total of 8 patients (57.2%) had primary metastatic cancer (stage IV), and 6 patients developed metastases after treatment of the primary cancer. All the patients had received 2-4 previous lines of chemotherapy and progressed.
Treatment and adverse events. The staring dose of FTD/TPI was 35 mg/m 2 , and the duration of treatment was 1-9 cycles (median, 5.8 cycles).
One patient had a delay of 1 week due to grade 3 neutropenia; none of the patients required dose reduction, and all patients eventually discontinued FTD/TPI due to disease progression. All treatment-related adverse events are listed in Table II .
Survival data. At the median follow-up time of 7.1 months (range, 1-14 months), the mPFS was 5 months [95% confidence interval (CI): 4.09-5.90], and the mOS was 7 months (95% CI: 5.95-8.04). The 6-month PFS was 35.7% and the 6-month OS was 57.1%. All 14 patients progressed on FTD/TPI treatment and 9 deaths were reported.
Increased PFS and OS were reported in patients with grade 3-4 neutropenia: The mPFS was 7 months in patients with neutropenia vs. 5 months in those without neutropenic events [hazard ratio (HR)= 0.24, 95% CI: 0.07-0.89; P= 0.033]; the mOS was 7 months in patients without neutropenia, whereas in the neutropenic group mOS was not met (HR=0.25, 95% CI: 0.06-1.14, P=0.075; Fig. 1) .
Furthermore, increased PFS and OS were observed in patients with a time of >18 months from the start of chemotherapy for mCRC, with a mPFS of 7 months vs. 5 months in patients with a shorter (≤18 months) previous treatment duration (HR= 0.15, 95% CI: 0.03-0.83, P= 0.029); the mOS was not met in patients with a time of >18 months, whereas it was 6 months in the ≤18 months patient group (HR=0.23, 95% CI: 0.05-1.12, P=0.069; Fig. 2 ).
Discussion
The aim of the present study was to compare survival and clinical data from the participants in the Lonsurf Compassionate (2) . Similar survival data were observed in the present retrospective study, with a mPFS of 5 months and a mOS of 7 months. The reports from other counties that participated in this Expanded Access program (4-6), revealed a similar trend in safety and efficacy. In the present study, grade 3-4 neutropenia was the most frequently observed clinically meaningful adverse event, occurring in 28% of the patients. This adverse event was associated with better treatment outcomes (mPFS of 7 months and increased mOS). Previously reported data demonstrated that, in patients with advanced colorectal cancer, FTD/TPI-induced severe neutropenia was associated with superior survival (2, (6) (7) (8) . The reported frequency of grade 3-4 neutropenia in FTD/TPI users is 31-50% (2,7-9). The global incidence of grade 3-4 neutropenia is quite low compared to the RECOURSE study, whereas the mPFS is relatively high. Despite the small number of included patients, it was observed that the time from the start of first-line chemotherapy to the start of FTD/TPI treatment may be a prognostic factor, as the mPFS in patients with a time of >18 months from the start of mCRC treatment was 7 months (HR= 0.15), and the HR for cancer-specific mortality was 0.23 (mOS was not met). It may be suggested that patients with a shorter duration of previous treatment lines and rapid progression under previous chemotherapy may benefit less from FTD/TPI treatment. This observation may lead to the hypothesis that more aggressive and chemotherapy-resistant tumors possibly harbor mutations leading to FTD/TPI resistance. Therefore, a variety of previous chemotherapy lines, patient performance status, primary tumor and metastases location may affect the duration of PFS and OS.
There were certain limitations to the present study. Due to the limited number of participants in the Lonsurf Compassionate Use program, the research was conducted on a small size of the mCRC population (n=14). Therefore, to generalize the results for a larger population, the study would require more participants.
In conclusion, severe neutropenia may be considered as a surrogate marker for predicting FTD/TPI treatment outcomes. In addition, patients with a time of <18 months from the start of first-line mCRC treatment to the first study drug administration have a poor prognosis. However, further studies are required to confirm these findings.
